Cargando…
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's reply
Autores principales: | Annane, Djillali, Grimaldi-Bensouda, Lamiae, Fremeaux-Bacchic, Véronique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070741/ https://www.ncbi.nlm.nih.gov/pubmed/33937736 http://dx.doi.org/10.1016/j.eclinm.2021.100866 |
Ejemplares similares
-
Complement inhibition in severe COVID-19 – Blocking C5a seems to be key
por: Lim, Endry H.T., et al.
Publicado: (2021) -
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study
por: Annane, Djillali, et al.
Publicado: (2020) -
The pandemic in French intensive care units—Author's response
por: Annane, Djillali
Publicado: (2021) -
Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
por: Mustafic, Hazrije, et al.
Publicado: (2021) -
Complement Inhibition and COVID-19: The Story so Far
por: Fodil, Sofiane, et al.
Publicado: (2021)